Short answer: yes, in limited circumstances. Since the FDA declared the GLP-1 shortages resolved, compounded semaglutide and tirzepatide may generally be prepared only for an individual patient when a licensed clinician documents a specific clinical reason the FDA-approved product is unsuitable for that patient. Cost and convenience are not clinical reasons.
This article is educational and is not medical advice. Whether any treatment is appropriate for you is decided by a licensed clinician after reviewing your health history.
Why were compounded GLP-1s so widely available before?
Federal law lets compounders prepare versions of a drug that is on the FDA's drug shortage list, under certain conditions (FDA Q&A). Tirzepatide and semaglutide were on that list during periods of high demand, which allowed broad compounding.
What changed?
| Medication | FDA declared shortage resolved |
|---|---|
| Tirzepatide (Zepbound, Mounjaro) | December 2024 |
| Semaglutide (Wegovy, Ozempic) | February 2025 |
Once a shortage is resolved, the shortage-based allowance ends. Compounding then has to rely on the ordinary rules for preparing a drug for an individual patient. See FDA: compounding laws and policies.
What counts as a valid clinical reason?
A licensed clinician must determine that a change from the approved product produces a significant difference for that specific patient — for example, a documented need the approved product cannot meet. A clinician cannot prescribe a compounded version simply because it costs less or is easier to get.
What should I watch out for?
- "Research use only" or "not for human consumption" products are not medications made for patients.
- Salt forms such as semaglutide sodium or semaglutide acetate are different active ingredients from the approved drug, and the FDA says they should not be used to compound semaglutide (FDA).
- No clinician review. A legitimate prescription requires a licensed clinician to review your health history.
How ElliotMeds approaches it
At ElliotMeds, a licensed U.S. clinician reviews every request and decides whether treatment is appropriate, asks for more information, or declines. Payment never guarantees a prescription, and if you're not approved you receive a full refund. Our semaglutide and tirzepatide guides cover each medication in detail.
Sources
- FDA — Compounding and the FDA: Questions and Answers
- FDA — Compounding laws and policies
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss
Regulatory status can change. This article reflects FDA guidance as of its last-updated date; check the FDA pages above for current information.
Every program includes a clinician chart review. When prescribed, treatments are filled by a licensed U.S. pharmacy.
Important note
Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing. A licensed clinician determines whether a treatment is appropriate based on the information provided.